SCHEMBL4159221

SCHEMBL4159221

CCCNS(=O)(=O)c1cc(C)ccc1C=C1c2ccccc2CCc2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 1/20 0.41
PGR P06401 1/20 0.41
NR3C2 P08235 1/20 0.41
AR P10275 1/20 0.41
NPSR1 Q6W5P4 3/20 0.40
ALDH1A1 P00352 3/20 0.40
POLB P06746 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
CA12 O43570 1/20 0.38
CA9 Q16790 1/20 0.38
MIF P14174 1/20 0.38
LMNA P02545 2/20 0.37
CYP3A4 P08684 2/20 0.37
SLC6A2 P23975 2/20 0.37
HTR2C P28335 2/20 0.37
HTR2B P41595 2/20 0.37
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
ADRB2 P07550 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4165313 0.91 NR3C1 (0.42) NR3C1PGRNR3C2ARNPSR1
SCHEMBL4155389 0.88 ALDH1A1 (0.41) NR3C1PGRNR3C2ARNPSR1
SCHEMBL4157513 0.87 CA12 (0.45) NR3C1PGRNR3C2ARNPSR1
SCHEMBL4161422 0.86 CYP3A4 (0.45) NR3C1PGRNR3C2ARNPSR1
SCHEMBL4162169 0.85 NR3C1 (0.44) NR3C1PGRNR3C2ARNPSR1
SCHEMBL4155365 0.85 NR3C1 (0.39) NR3C1PGRNR3C2ARNPSR1
SCHEMBL4175519 0.84 NR3C1 (0.39) NR3C1PGRNR3C2ARNPSR1
SCHEMBL8351185 0.82 NR3C1 (0.50) NR3C1PGRNR3C2ARNPSR1
SCHEMBL4163915 0.81 L3MBTL1 (0.48) NR3C1PGRNR3C2ARNPSR1
SCHEMBL4170995 0.81 AR (0.44) NR3C1PGRNR3C2ARNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2006-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS NR5A1, NR3C2, NR3C1 NR3C1 3/4885PGR 54/4885NR3C2 2/4885
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators NR5A1, NR3C2, NR3C1 NR3C1 3/4885PGR 50/4885NR3C2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.